Business Wire

Lipella’s Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial

PITTSBURGH--(BUSINESS WIRE)--Pittsburgh based Lipella Pharmaceuticals Inc. today announced newly published results of a multi-site, double-blind, placebo-controlled clinical trial comparing the ...
Yahoo Finance

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical ...
Pharmabiz

Lipella Pharma receives US FDA nod for expanded access programme for LP-310, an oral rinse formulation to treat oral lichen planus

Lipella Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing innovative therapies by reformulating active agents in existing generic drugs, announced that the US Food and ...
Seeking Alpha

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for ...
The Globe and Mail

COVID-19 Treatment Landscape: FDA Approves Updated COMIRNATY LP.8.1 COVID-19 Vaccine | DelveInsight’s Perspective on Market Impact, Patient Population and Pipeline Therapies

DelveInsight Business Research's latest analysis highlights the significant impact of the FDA's approval of Pfizer and BioNTech's updated COMIRNATY LP.8.1-adapted monovalent COVID-19 vaccine on August ...